Optos is celebrating its positive impact on retinal imaging technology and the advancement of patient care over 30 years, having installed 25,000 devices worldwide, and published 2,500 clinical and peer-reviewed studies spanning 235 disease states.
Acknowledging the support, feedback and partnership of customers, Optos Chief Executive Officer Robert Kennedy said the “remarkable double milestone reflects the unwavering commitment that Optos has had to innovation and excellence in providing the best and clinically-relevant technology available”.
Optos has the only single capture, 200 degree, ultra-widefield retinal imaging technology, and a total of nine imaging modalities across all device platforms, including the recent addition of optomap color rgb, natural colour and optomap blue fundus autofluorescence imaging modalities. The company’s combined imaging devices integrate ultra-widefield retinal imaging with optomap-guided optical coherence tomography, providing clinicians with comprehensive insights into retinal health.
Optos technology seamlessly integrates into a variety of healthcare settings from telehealth to retina, streamlining workflows and enhancing practice efficiency without compromising quality.
For more information about Optos and its industry-leading retinal imaging technology, visit the Optos website.
